Advancing dermatology patients’ quality of life through digital health innovations: a comprehensive systematic review Authors: Xinjin Liu, Yifei Cheng, Xu Liu, Yichen Liu, Dingling Li, Weihong Guo, Haoyu Jiang, Xian Jiang, Linghong Guo Published: 2026 ABSTRACT Digital health interventions (DHIs) are increasingly used in dermatology to improve patients’ quality of life (QoL). This systematic review (PROSPERO: CRD420250628076) synthesized 14 studies categorized into four WHO intervention types, including telemedicine, targeted client communication, personal health tracking, and client-to-client communication, and evaluated for their effects on QoL and related psychosocial outcomes. Among telemedicine studies (n = 8), six reported non inferior or superior QoL versus in person care. Targeted client communication (n = 4) showed mixed QoL effects but improved mental health and self efficacy. Personal health tracking (n = 1) did not significantly improve QoL, while client to client communication (n = 1) provided psychosocial support. Overall, DHIs may improve QoL in dermatology, but evidence is limited by methodological heterogeneity, risk of bias, and short follow up. Future evaluations should prioritize standardized core outcome sets and integrate AI with in time adaptive interventions to deliver personalized psychological support, ensuring algorithmic equity from the outset. Introduction Dermatologic conditions affect over one-third of the global population, presenting as a diverse spectrum of disorders that result in lasting physical, psychological, and social impairments1–5. While many of these conditions are chronic and inflammatory, such as psoriasis, acne, and atopic dermatitis, others include acute inflammatory states and skin malignancies such as melanoma. These diseases compromise not only skin integrity but also emotional stability, sleep quality, and self-image6–8. The psychosomatic burden of visible skin disease is substantial-frequently reinforcing a cycle of stress-induced flare-ups, reduced social participation, and deteriorating mental health9–14. The concept of quality of life (QoL) in dermatology encompasses functional capacity, emotional well-being, social interaction, and perception of appearance15. In this context, traditional face-to-face care, while effective for clinical diagnosis and acute treatment, often fails to address the persistent, day-to-day psychosocial challenges patients face. Constraints such as limited consultation time, geographic barriers to specialists, and the episodic nature of clinic visits often leave patients without adequate longitudinal support for self-management and emotional resilience16–18. With technological advancements, digital health interventions (DHIs) have emerged to bridge these care gaps. The World Health Organization (WHO) defines DHIs as discrete functions of a digital technology to achieve health sector objectives19. In previous literature, DHIs are not merely passive conduits for traditional care; rather, their inherent digital functionalities such as asynchronous image sharing, real-time symptom tracking, and automated feedback, serve as active components and behavioral change techniques that may independently influence clinical and psychosocial outcomes20,21. These approaches hold special relevance for dermatology due to its visual nature, need for ongoing self-management, and high prevalence of remote consultation use22–27. While prior research has explored specific DHIs in dermatology, few synthesize how such interventions holistically impact QoL across a broad range of dermatologic conditions26,28,29. Moreover, mechanisms linking these interventions to clinical and psychosocial improvements remain under-characterized. Research has established that improvements in self-efficacy, emotional resilience, and social functioning often drive overall QoL enhancement in chronic dermatology30. Consequently, evaluating the true impact of DHI requires a multidimensional approach that captures not only global QoL but also these closely related patient-centered psychosocial outcomes. Therefore, this systematic review aims to comprehensively evaluate the efficacy of DHIs on QoL and associated psychosocial outcomes in dermatologic patients. To address the conceptual ambiguity between a delivery modality and the intervention itself, this review conceptualizes DHIs as complex interventions rather than passive communication platforms. To provide a standardized synthesis, we systematically mapped the evaluated DHIs based on the WHO Classification of DHIs31. By mapping these interventions to established WHO domains, this review seeks to clarify the differential effects of various DHIs on patient QoL, ultimately providing actionable evidence for integrating digital health into dermatologic care. Results Study selection and characteristics A total of 1955 studies were initially retrieved from four major databases. After excluding non-original research and duplicates, 901 articles remained. These were screened based on predefined inclusion and exclusion criteria, ultimately resulting in 12 eligible studies32–43. Additionally, two highly relevant articles published after the database search were identified through manual citation tracking and journal alerts44,45, bringing the total number of included studies to 14 (Fig. 1).Fig. 1Preferred reporting items for systematic reviews flow diagram for selection of studies.This figure was created using Microsoft PowerPoint based on the PRISMA template. Preferred reporting items for systematic reviews flow diagram for selection of studies. This figure was created using Microsoft PowerPoint based on the PRISMA template. The methodological designs of the included literature exhibited significant diversity, including 6 randomized controlled trials (RCTs)33–35,39,40,45, 2 cross-sectional studies32,43, 5 single-arm interventional studies36–38,41,42 and 1 observational study44. Geographically, the research was conducted across diverse regions, predominantly in Europe (n = 5; e.g., Germany, UK, Denmark, Iceland)35,40,42–44 and North America (n = 3; USA)32–34, with additional studies from Australia (n = 2)38,41, China (n = 1)36, and a multinational setting (n = 3)37,39,45. Regarding sampling approaches, RCTs frequently utilized random sampling33–35,39,40,45, while single-arm, cross-sectional and observational studies largely employed convenience sampling32,36–38,41–44. Sample sizes ranged significantly from 11 participants in a pilot feasibility trial41 to 677 participants in large-scale RCTs40. Across the included studies, mean participant age ranged from 19.3 ± 3.4 years40 to 67 (46–82)38 years, only three studies specifically reported outcomes for older adults (mean age >60 years)33,38,41. The gender distribution reflected the specific targeted conditions. The overall proportion of females ranged from 0% in androgenetic alopecia43 to 92% in carers of children with atopic dermatitis40. The DHIs targeted a broad spectrum of dermatologic conditions. The most frequently evaluated specific diseases were psoriasis (n = 3)32,34,37 and atopic dermatitis or eczema (n = 3)35,40,42. Other targeted conditions included melanoma (n = 2)38,41, chronic spontaneous urticaria (n = 1)44, acne (n = 1)36, and androgenetic alopecia (n = 1)43, while three studies enrolled patient cohorts with mixed general dermatologic conditions33,39,45. The types of DHI were also diverse. In studies utilizing controlled designs (n = 6), the primary comparators were face-to-face consultations33,34,39,45 or usual clinical practice35,40. Mapped to the WHO classification, the majority of studies (n = 8) investigated telemedicine, encompassing real-time video consultations or asynchronous store-and-forward image transfers33,34,38,39,41,43–45. The remaining studies evaluated targeted client communication (n = 4)36,37,40,42, personal health tracking (n = 1)35, and client-to-client communication (n = 1)32. Follow-up durations ranged from single cross-sectional assessments to longitudinal follow-ups of up to 12 months. The key study characteristics are shown in Table 1. The sample recruitment and baseline information of included studies are listed in Supplementary Table 1. A detailed description of each digital health intervention following the Template for Intervention Description and Replication (TIDieR) checklist is provided in Supplementary Table 2. The yearly distribution and types of included studies are illustrated in Supplementary Fig. 1.Table 1Key characteristics of included studiesCategoryStudy (Year, Country)Study DesignSample SizeDermatologic ConditionDHIsComparatorFollow-up DurationQoL measureQoL FindingsTelemedicineWhited et al., 2013 (USA)RCTN = 391Mixed dermatologic conditionsStore-and-forward teledermatology for managing consultationsIn-person dermatology consultation9 monthsSkindex-16Significant improvement in Skindex-16 scores over 9 monthsArmstrong et al., 2019 (USA)RCTN = 296PsoriasisOnline, collaborative connected-health modelIn-person dermatology consultation12 monthsSkindex-16, DLQIOnline care model was found to be equivalent to in-person care in improving quality of lifeLopez-Liria et al., 2022 (USA&Spain)RCTN = 450Mixed dermatologic conditionsAsynchronous teledermatology(TD)Monitored conventionally in the hospitalf (F-F/D)6 monthsEQ-5D-5L and Skindex-29Improving HRQoL outcomes over conventional hospital visitsLai-Kwon et al., 2022 (Australia)Single-arm interventional studyN = 31 (Consented) / 30 (Completed intervention)Metastatic melanomaTelehealth survivorship program consisted of nurse-led consultations (MELCARE)None (Single-arm)3 monthsNo (Psychosocial needs were assessed using the Distress Thermometer and a bespoke problem list)The intervention led to a significant improvement in psychological well-beingCrosby et al., 2023 (Australia)Single-arm interventional studyN = 11Advanced melanomaSupervised telehealth exercise (accredited exercise physiologist (AEP) via the online video conferencing platform Zoom (Zoom Inc))None (Single-arm)8 weeksEORTC QLQ-C30QoL was preserved despite patients undergoing checkpoint inhibitor therapyvon Büren et al., 2023 (Germany)Cross-sectional studyN = 191Androgenetic alopecia (AGA)Direct-to-consumer teledermatology platformNone (Cross-sectional)6 weeksNo (QoL-related outcomes were assessed using a custom questionnaire)Teledermatology has potential to have a positive impact on QoL is demonstrated by the finding that self-esteem improvedHindelang et al., 2025 (Germany)Prospective observational studyN = 24Chronic spontaneous urticaria (CSU)Digital platform (medflex)None (Single-arm)12 monthsDLQIDLQI improved significantly over the 12-month periodLopez-Villegas et al., 2025 (USA&Spain)RCTN = 450Mixed dermatologic conditionsDigital platform (Telederma)In-person dermatology consultation6 monthsEQ-5D-5LImproving HRQoL outcomes over conventional hospital visits, and more Quality-Adjusted Life YearsTargeted client communicationLiu et al., 2020 (China)Single-arm interventional studyN = 30AcneDermatological Live Chat BotNone (Pre-post comparison)4 weeksDLQI and CADIBoth CADI and DLQI scores decreased significantly after 4 weeksFortune et al., 2022 (Ireland & USA)Single-arm interventional studyN = 66 (Recruited) 34 (Completed)PsoriasisDigital therapeutic app (Allay)None (Single-arm)12 weeksDLQIPositive improvement trends in DLQISanter et al., 2022 (UK)Two independent RCTsN = 677 (340 carers of children + 337 young people)Eczema (Atopic Dermatitis)Online behavioural interventions in addition to usual care(Eczema Care Online, ECO)Usual care (Standard informational website)24 weeks (primary) and up to 52 weeksCHU-9D for children, EQ-5D-5L for young peopleNo differences between the DHIs and usual care cohortsGudmundsdóttir et al., 2023 (Iceland)Single-arm interventional studyN = 21Atopic DermatitisMobile app delivering education, medication reminders, and lifestyle coachingNone (Single-arm)6 weeksQoL PROSQoL PROs improved over timePersonal health trackingJoergensen et al., 2020 (Denmark)RCTN = 83Atopic dermatitisMemory button and supportive app for tracking topical treatments1): control group 2): participants only received the memory buttons1 monthDLQINo significant improvement was observed in QoLClient-to-client communicationIdriss et al., 2009 (USA)Cross-sectional studyN = 260PsoriasisOnline support communities providing resources and peer adviceNone (Cross-sectional)Cross-sectionalDLQI, Non-validated QuestionsAround half the respondents perceived improvements in their QoL Table 1Key characteristics of included studiesCategoryStudy (Year, Country)Study DesignSample SizeDermatologic ConditionDHIsComparatorFollow-up DurationQoL measureQoL FindingsTelemedicineWhited et al., 2013 (USA)RCTN = 391Mixed dermatologic conditionsStore-and-forward teledermatology for managing consultationsIn-person dermatology consultation9 monthsSkindex-16Significant improvement in Skindex-16 scores over 9 monthsArmstrong et al., 2019 (USA)RCTN = 296PsoriasisOnline, collaborative connected-health modelIn-person dermatology consultation12 monthsSkindex-16, DLQIOnline care model was found to be equivalent to in-person care in improving quality of lifeLopez-Liria et al., 2022 (USA&Spain)RCTN = 450Mixed dermatologic conditionsAsynchronous teledermatology(TD)Monitored conventionally in the hospitalf (F-F/D)6 monthsEQ-5D-5L and Skindex-29Improving HRQoL outcomes over conventional hospital visitsLai-Kwon et al., 2022 (Australia)Single-arm interventional studyN = 31 (Consented) / 30 (Completed intervention)Metastatic melanomaTelehealth survivorship program consisted of nurse-led consultations (MELCARE)None (Single-arm)3 monthsNo (Psychosocial needs were assessed using the Distress Thermometer and a bespoke problem list)The intervention led to a significant improvement in psychological well-beingCrosby et al., 2023 (Australia)Single-arm interventional studyN = 11Advanced melanomaSupervised telehealth exercise (accredited exercise physiologist (AEP) via the online video conferencing platform Zoom (Zoom Inc))None (Single-arm)8 weeksEORTC QLQ-C30QoL was preserved despite patients undergoing checkpoint inhibitor therapyvon Büren et al., 2023 (Germany)Cross-sectional studyN = 191Androgenetic alopecia (AGA)Direct-to-consumer teledermatology platformNone (Cross-sectional)6 weeksNo (QoL-related outcomes were assessed using a custom questionnaire)Teledermatology has potential to have a positive impact on QoL is demonstrated by the finding that self-esteem improvedHindelang et al., 2025 (Germany)Prospective observational studyN = 24Chronic spontaneous urticaria (CSU)Digital platform (medflex)None (Single-arm)12 monthsDLQIDLQI improved significantly over the 12-month periodLopez-Villegas et al., 2025 (USA&Spain)RCTN = 450Mixed dermatologic conditionsDigital platform (Telederma)In-person dermatology consultation6 monthsEQ-5D-5LImproving HRQoL outcomes over conventional hospital visits, and more Quality-Adjusted Life YearsTargeted client communicationLiu et al., 2020 (China)Single-arm interventional studyN = 30AcneDermatological Live Chat BotNone (Pre-post comparison)4 weeksDLQI and CADIBoth CADI and DLQI scores decreased significantly after 4 weeksFortune et al., 2022 (Ireland & USA)Single-arm interventional studyN = 66 (Recruited) 34 (Completed)PsoriasisDigital therapeutic app (Allay)None (Single-arm)12 weeksDLQIPositive improvement trends in DLQISanter et al., 2022 (UK)Two independent RCTsN = 677 (340 carers of children + 337 young people)Eczema (Atopic Dermatitis)Online behavioural interventions in addition to usual care(Eczema Care Online, ECO)Usual care (Standard informational website)24 weeks (primary) and up to 52 weeksCHU-9D for children, EQ-5D-5L for young peopleNo differences between the DHIs and usual care cohortsGudmundsdóttir et al., 2023 (Iceland)Single-arm interventional studyN = 21Atopic DermatitisMobile app delivering education, medication reminders, and lifestyle coachingNone (Single-arm)6 weeksQoL PROSQoL PROs improved over timePersonal health trackingJoergensen et al., 2020 (Denmark)RCTN = 83Atopic dermatitisMemory button and supportive app for tracking topical treatments1): control group 2): participants only received the memory buttons1 monthDLQINo significant improvement was observed in QoLClient-to-client communicationIdriss et al., 2009 (USA)Cross-sectional studyN = 260PsoriasisOnline support communities providing resources and peer adviceNone (Cross-sectional)Cross-sectionalDLQI, Non-validated QuestionsAround half the respondents perceived improvements in their QoL Key characteristics of included studies Quality of life and related patient-centered outcomes All 14 included studies reported at least one QoL-related outcome, either via validated instruments (n = 11)32–37,39–41,44,45 or custom psychosocial measures (n = 3)38,42,43. The assessment of QoL relied on a variety of established instruments, most notably the Dermatology Life Quality Index (DLQI) (n = 6)32,34–37,44, the EQ-5D (n = 3)39,40,45, Skindex variants33,34,39, Child Health Utility-9D (CHU-9D) for children40, Cardiff Acne Disability Index (CADI) for acne patients36, and oncology-specific questionnaires, like European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire Version 3 (EORTC QLQ-C30)41. Alongside global QoL instruments, 9 studies reported secondary patient-centered outcomes32–34,36–38,40,43,44. All patient-related outcomes were categorized into three fundamental domains based on the PROMIS framework46,47: 1) Mental Health; 2) Self-Efficacy; and 3) Social Health. Figure 2 shows the effectiveness of DHIs across outcome domains. The classification of these outcomes by study is presented in Supplementary Table 3.Fig. 2Effectiveness of digital health interventions across outcome domains.This figure was created using Microsoft PowerPoint. Effectiveness of digital health interventions across outcome domains. This figure was created using Microsoft PowerPoint. Telemedicine Within the telemedicine domain (n = 8)33,34,38,39,41,43–45, evaluations of QoL-related psychosocial constructs were conducted across 4 RCTs33,34,39,45, 2 single-arm interventional studies38,41, 1 observational study44 and 1 cross-sectional study43. These studies primarily utilized the DLQI, Skindex, and EQ-5D instruments. Regarding overall QoL, 3 RCTs compared teledermatology to conventional face-to-face consultations33,34,39. Armstrong et al. (N = 296) conducted an RCT evaluating an online collaborative care model for psoriasis, suggesting that Skindex-16 score reduction in the remote group was equivalent to that of the conventional in-person group34. Similarly, Whited et al.(N = 389) evaluated an asynchronous store-and-forward system for mixed dermatologic conditions, showing non-inferior QoL improvements on the Skindex-1633. Lopez-Liria et al. and Lopez-Villegas et al. (N = 450) found that an asynchronous teledermatology system improved QoL more than conventional face-to-face visits for patients with mixed dermatologic conditions39,45. In an observational study, Hindelang et al. (N = 24) observed an improvement in DLQI scores over 12 months among chronic spontaneous urticaria patients using a digital platform for routine follow-ups, without a control group comparison44. In oncology settings, Lai-Kwon et al. (N = 31) reported that MELCARE, a nurse-led telehealth survivorship program, maintained overall QoL in metastatic melanoma survivors38. In evaluating patient-related outcomes, the evidence within this domain was categorized into mental health (n = 5)33,34,38,43,44 and self-efficacy (n = 1)44. Regarding mental health, both Whited et al. and Armstrong et al. suggested that telemedicine models are as effective as in-person care in reducing disease-related emotional distress33,34. Similarly, Lai-Kwon et al. found that telehealth mitigated psychological burden38, and Hindelang et al. noted that DHIs maintained patients’ well-being44. von Büren et al. observed that teledermatology was associated with improvements in QoL, with 59% of men with androgenetic alopecia reporting improved self-esteem within six weeks of therapy via a digital platform43. In the domain of self-efficacy, Hindelang et al. found that DHIs made it easier for patients to track their treatment plans and organize their lives more autonomously44. Targeted client communication Among studies evaluating targeted client communication (n = 4)36,37,40,42, QoL and patient-related outcomes were assessed through 1 RCT40 and 3 single-arm interventional studies36,37,42, relying on the DLQI, EQ-5D, CADI and custom PROs. Regarding overall QoL, findings were mixed across studies. Santer et al. conducted two independent RCTs focusing on atopic dermatitis, including carers of 340 children and 337 young people40. Their findings indicated that the use of an online behavioral intervention, Eczema Care Online, observed no differences between the DHI and usual care cohorts in improving QoL. Liu et al. investigated an intervention that combined a self‑regulation‑based patient education module with a mobile application featuring an artificial intelligence (AI)‑powered live chat bot for acne patients(N = 30)36. After 4 weeks, the intervention reduced CADI scores (from 7.45 to 4.15, p < 0.001), and QoL also improved (with DLQI from 11.34 to 4.70, p < 0.001), indicating alleviation of disease‑related disability and daily life disruptions caused by acne. Furthermore, Fortune et al. (N = 66) reported that participants completing the digital therapeutic program experienced improvements in their psoriasis-specific quality of life, as measured by the DLQI (p = 0.002, d = 1.06), with covariate analysis revealing an interaction between physical symptom reduction and dermatology-specific QoL improvements (F[1,31] = 60.92, p = 0.001, d = 2.84)37. Gudmundsdóttir et al. (N = 21) prospectively evaluated an app integrating health education and lifestyle coaching42, all users reported improvements in QoL PROs over time. Beyond QoL improvements, targeted client communication interventions offer benefits in related patient-centered outcomes, specifically within the domains of mental health (n = 1)37 and self-efficacy (n = 3)36,37,40. Regarding mental health, Fortune et al. noted that DHI-based education reduced clinical depression rates (p = 0.004,d = 0.96)37. In the domain of self-efficacy, Liu et al. reported improvements in disease-coping efficacy after a 4-week intervention (mean ASRI scores rising from 56.09 to 70.07, p < 0.001)36. Similarly, Fortune et al. observed increased psychological resilience among users (p = 0.01,d = 0.66)37. Santer et al. found that at 24 weeks, DHIs improved enablement scores for both parent/carer (adjusted mean difference: −0.7, 95% CI: −1.0 to −0.4) and young adult cohorts (adjusted mean difference: −0.9, 95% CI: −1.3 to −0.6), better equipping them to actively manage their condition40. Personal health tracking Consistent with our inclusion criteria, one study evaluating a personal health tracking intervention was retained (n = 1)35. This intervention involved medication reminders rather than monitoring alone. QoL was assessed using the DLQI, while objective disease severity metrics were reported separately as contextual clinical outcomes. In this RCT, Joergensen et al. (N = 83) explored combining an electronic memory button with a tracking app for atopic dermatitis35. After one month, the intervention group showed decreases in objective disease severity and daily symptom burden, but overall QoL did not significantly differ between groups. Client-to-client communication The single observational survey (n = 1) focusing on client-to-client communication utilized subjective self-reported assessments to evaluate the impact of online community engagement on overall QoL32. Regarding overall QoL, Idriss et al. conducted a comprehensive survey evaluating 260 active participants across five online support communities for psoriasis32. The data suggested that although these active users generally faced significant QoL impairment at baseline, around half the respondents (49.5%) perceived improvements in their QoL since becoming an online support site user. Beyond QoL improvements, client-to-client communication interventions offer benefits in related patient-centered outcomes, specifically within the domains of self-efficacy and social health (n = 1)32. Regarding self-efficacy, Idriss et al. found that 65.7% of surveyed patients felt online support communities helped them regain a sense of control over their condition. In the domain of social health, digital peer interactions were reported as valuable, with most users discovering peers who actively listened (59.2%) and helped with personal emotional issues (54.2%). Implementation and engagement outcomes Implementation-related outcomes, including engagement, acceptability, and satisfaction, were reported in 13 studies32–35,37–45. Engagement and feasibility Eleven studies reported engagement and feasibility with DHIs, and together showed mixed findings32–35,37,38,40–44. A majority of studies (n = 7)32,34,35,38,40,42,44 demonstrated high intervention completion and longitudinal retention rates. Specifically, several programs achieved high retention, such as Lai-Kwon et al. (97%)38 and Hindelang et al. (96% over 12 months)44. Gudmundsdóttir et al. reported a 95% short-term completion rate42. Long-term feasibility was further validated. Armstrong et al. found that an online care model achieved an 89% retention rate over 12 months, comparable to the 91% in traditional care34. Santer et al. found the 24-week follow-up rates exceeding 90% for both carers and young patients40. Additionally, Joergensen et al. reported an 86.5% completion rate for a multi-modal system35, and Idriss et al. observed an 87.5% weekly engagement rate within online forums32. Conversely, some studies (n = 4) reported challenges regarding initial uptake and long-term program completion33,37,41,42. Whited et al. noted an initial uptake rate of 34%33, and Crosby et al. reported a moderate initial recruitment rate of 48% among advanced melanoma patients41. Fortune et al. showed a 51.5% completion rate over 12 weeks37. Furthermore, Gudmundsdóttir et al. found that while overall completion was high, participation in non-mandatory tasks was significantly lower42. Despite these variations, von Büren et al. reported that 87% of patients maintained engagement to the DHI protocols43. Acceptability and satisfaction Patient acceptability and satisfaction were consistent across 9 studies32–34,37,38,41–44. Quantitative evidence from Whited et al. showed no significant difference in satisfaction between teledermatology (86.8%) and in-person care (92.1%)33. High acceptability was further supported by a 100% recommendation rate in Lai-Kwon et al.38, a 92% preference for DHI-based care in Hindelang et al.44, a high usability score of 6.2/7 in Gudmundsdóttir et al.42, and an 88% clinical tolerance rate in Crosby et al.41. Qualitative data aligned with these findings. Fortune et al. noted that patients requested continued access post-study37. Idriss et al. reported that the perceived utility of online support (86.5%) was higher than that of traditional consultations (51.9%)32. Armstrong et al. found that patients described the DHI as safe, accessible, equitable, and efficient34. Regarding barriers to acceptability, Armstrong et al. found patient embarrassment regarding sensitive area imaging34. Healthcare efficiency and access At the system level, several studies (n = 7) suggested that DHIs were associated with healthcare efficiency and access outcomes32–34,39,40,44,45. Idriss et al. identified geographic and scheduling barriers associated with traditional care32. Similarly, Armstrong et al. reported a reduction in unnecessary specialist referrals34, and Whited et al. observed a decrease in required clinic visits from 1.55 to 1.10 over 9 months33. Physicians in the study by Hindelang et al. reported that remote applications were clinically reliable and time-saving44. Regarding economic outcomes, Armstrong et al. noted the near elimination of patient travel burdens34. Lopez-Villegas et al. showed that teledermatology saved patients both time (59.73 minutes) and total personal costs (77.59%)39, and further indicated that patients using this platform gained more Quality-Adjusted Life Years (+0.05 QALYs) compared to those receiving standard care45. Finally, Santer et al. highlighted the public health value of these interventions, driven by their low cost, high scalability, and absence of identifiable harms40. Risk of bias and quality assessment Overall, the methodological quality of the included studies (n = 14) varied substantially, ranging from low to high risk of bias across different study designs (Table 2). Among the RCTs (n = 6)33–35,39,40,45, assessments using the Cochrane Risk of Bias 2 (RoB 2) tool48 revealed mixed methodological quality (Figs. 3 & 4). Two studies39,45 were judged to have a low risk of bias, two34,40 raised some concerns, and two33,35 were evaluated as high risk. The domains contributing to elevated risk ratings included outcome measurement and the randomization process. For non-randomized interventional studies (single-arm designs, n = 5)36–38,41,42, evaluation using the ROBINS-I tool49 indicated that two studies36,41 were assessed at a moderate risk of bias, and serious risk in three37,38,42 (Figs. 5 & 6). Observational and cross-sectional studies (n = 3)32,43,44, evaluated using the Joanna Briggs Institute (JBI) critical appraisal tools50, showed low risk of bias in two studies32,44 and moderate risk in one study43.Fig. 3Risk of bias graph of RCTs (RoB 2 tool).The risk of bias visualization was were performed by using Hiplot (ORG) (https://hiplot.org).Fig. 4Risk of bias summary of RCTs (RoB 2 tool).The risk of bias visualization was were performed by using Hiplot (ORG) (https://hiplot.org).Fig. 5Risk of bias graph of non-randomized interventional studies (ROBINS-I V2 tool).The risk of bias visualization was were performed by using Hiplot (ORG) (https://hiplot.org).Fig. 6Risk of bias summary of non-randomized interventional studies (ROBINS-I V2 tool).The risk of bias visualization was were performed by using Hiplot (ORG) (https://hiplot.org).Table 2Summary of risk of bias and quality assessmenta Risk of Bias of the Randomized Controlled Trials (RCTs) Assessed Using the RoB 2.0 ToolStudy IDRandomization processDeviations from intended interventionsMising outcome dataMeasurement of the outcomeSelection of the reported resultOverall BiasLopez-Villegas et al., 2024LowLowLowLowLowLowLopez-Liria et al., 2022LowLowLowLowLowLowSanter et al., 2022LowLowLowSome concernsLowSome concernsJoergensen et al., 2020Some concernsLowLowHighSome concernsHighArmstrong et al., 2019LowLowLowSome concernsLowSome concernsWhited et al., 2013LowLowLowHighLowHighb Risk of bias of the single-arm studies assessed using the ROBINS-I V2 toolStudy IDBias due to confoundingBias in classification of interventionsBias in selection of participants into the studyBias due to missing dataBias arising from measurement of the outcomeBias in selection of the reported resultOverall assessmentCrosby et al., 2023ModerateLowLowModerateModerateModerateModerateGudmundsdóttir et al., 2023ModerateLowLowLowSeriousLowSeriousFortune et al., 2022SeriousLowModerateModerateModerateLowSeriousLai-Kwon et al., 2022ModerateLowLowLowSeriousLowSeriousLiu et al., 2020ModerateLowLowLowModerateLowModeratec Quality Assessment of Observational and Cross-sectional studies appraised using the Joanna Briggs Institute (JBI) critical appraisal toolsStudy IDWere the criteria for inclusion in the sample clearly defined?Were the study subjects and the setting described in detail?Was the exposure measured in a valid and reliable way?Were objective, standard criteria used for measurement of the condition?Were confounding factors identified?Were strategies to deal with confounding factors stated?Were the outcomes measured in a valid and reliable way?Was appropriate statistical analysis used?Overall assessmentHindelang et al., 2024YesYesYesYesYesUnclearYesYesLowvon Büren et al., 2023YesYesYesUnclearYesYesUnclearYesModerateIdriss et al., 2009YesYesUnclearUnclearYesYesYesYesLow Risk of bias graph of RCTs (RoB 2 tool). The risk of bias visualization was were performed by using Hiplot (ORG) (https://hiplot.org). Risk of bias summary of RCTs (RoB 2 tool). The risk of bias visualization was were performed by using Hiplot (ORG) (https://hiplot.org). Risk of bias graph of non-randomized interventional studies (ROBINS-I V2 tool). The risk of bias visualization was were performed by using Hiplot (ORG) (https://hiplot.org). Risk of bias summary of non-randomized interventional studies (ROBINS-I V2 tool). The risk of bias visualization was were performed by using Hiplot (ORG) (https://hiplot.org). Table 2Summary of risk of bias and quality assessmenta Risk of Bias of the Randomized Controlled Trials (RCTs) Assessed Using the RoB 2.0 ToolStudy IDRandomization processDeviations from intended interventionsMising outcome dataMeasurement of the outcomeSelection of the reported resultOverall BiasLopez-Villegas et al., 2024LowLowLowLowLowLowLopez-Liria et al., 2022LowLowLowLowLowLowSanter et al., 2022LowLowLowSome concernsLowSome concernsJoergensen et al., 2020Some concernsLowLowHighSome concernsHighArmstrong et al., 2019LowLowLowSome concernsLowSome concernsWhited et al., 2013LowLowLowHighLowHighb Risk of bias of the single-arm studies assessed using the ROBINS-I V2 toolStudy IDBias due to confoundingBias in classification of interventionsBias in selection of participants into the studyBias due to missing dataBias arising from measurement of the outcomeBias in selection of the reported resultOverall assessmentCrosby et al., 2023ModerateLowLowModerateModerateModerateModerateGudmundsdóttir et al., 2023ModerateLowLowLowSeriousLowSeriousFortune et al., 2022SeriousLowModerateModerateModerateLowSeriousLai-Kwon et al., 2022ModerateLowLowLowSeriousLowSeriousLiu et al., 2020ModerateLowLowLowModerateLowModeratec Quality Assessment of Observational and Cross-sectional studies appraised using the Joanna Briggs Institute (JBI) critical appraisal toolsStudy IDWere the criteria for inclusion in the sample clearly defined?Were the study subjects and the setting described in detail?Was the exposure measured in a valid and reliable way?Were objective, standard criteria used for measurement of the condition?Were confounding factors identified?Were strategies to deal with confounding factors stated?Were the outcomes measured in a valid and reliable way?Was appropriate statistical analysis used?Overall assessmentHindelang et al., 2024YesYesYesYesYesUnclearYesYesLowvon Büren et al., 2023YesYesYesUnclearYesYesUnclearYesModerateIdriss et al., 2009YesYesUnclearUnclearYesYesYesYesLow Summary of risk of bias and quality assessment Discussion To our knowledge, this is the first systematic review to comprehensively evaluate both the specific types of DHIs and their multidimensional impacts on the QoL in dermatology patients. By synthesizing evidence from 14 eligible studies and mapping them to the WHO classification, our findings indicate that DHIs may provide potential benefits across multiple QoL domains, though efficacy varies significantly by intervention modality. Among the evaluated types, telemedicine possesses the most substantial evidence base. RCTs comparing teledermatology with conventional face‑to‑face care found it to be non‑inferior in improving QoL33,34,39,45, aligning with previous systematic reviews51. While traditional in-person consultations remain the gold standard for absolute diagnostic accuracy, previous studies demonstrate that teledermatology achieves high diagnostic concordance while reducing time to diagnosis and enhancing patient satisfaction27,52. Furthermore, findings regarding cost-savings and QALY gains45 echo the growing body of health economic evidence supporting telemedicine as a sustainable solution for overstretched healthcare systems53. However, due to the highly variable risk of bias across these trials, the QoL benefits of telemedicine should be viewed as promising trends rather than definitive evidence. Interventions using targeted client communication showed mixed effects on global QoL but consistently improved self‑efficacy and mental health36,37,40,42. This pattern also finds support in systematic reviews of other chronic conditions, such as end‑stage kidney disease, where digital health interventions significantly improve depression but the evidence for overall QoL changes is of low quality54. Personal health tracking reduced disease severity but did not translate into QoL improvement35, a phenomenon likely attributable to “tracking fatigue” that can emerge when self-monitoring lacks integrated clinical feedback55. Meanwhile, client‑to‑client communication showed that online communities were perceived as valuable by most users32. Given the profound psychosocial stigma and altered body image associated with visible skin conditions56, digital peer-to-peer platforms may address an important unmet need by providing experiential knowledge and emotional validation that common clinical encounters often lack57. However, the cross‑sectional design of current evidence precludes causal inference. Most studies reported high retention rates (85‑97%) and satisfaction32,34,35,38,40,42,44, suggesting that DHIs are acceptable in practice. Nonetheless, noted barriers such as low initial uptake33,41, poor engagement with non‑mandatory tasks42, and patient embarrassment about imaging sensitive areas34, highlight significant real-world challenges. Qualitative research further emphasizes concerns about data privacy, digital literacy among older patients, workflow integration, and reimbursement58,59. Consequently, hybrid care models that integrate digital triage with traditional in-person consultations may represent a more realistic and acceptable pathway for implementation60. Such hybrid approaches are exemplified by Liu et al., who combined in‑person educational module with an AI‑powered mobile chat bot as an adjunctive digital support for acne patients36. The evidence gaps identified in this review suggest that static, one‑size‑fits‑all DHIs may be insufficient for the complex psychosocial needs of dermatology patients. AI and personalisation are future directions. The evolution toward precision dermatology envisions AI-powered digital assistants capable of integrating multidimensional clinical and patient-generated data to predict disease flares61. To translate these predictive capabilities into meaningful psychosocial benefits, future digital health models may adopt the framework of Just-in-Time Adaptive Interventions (JITAIs). By leveraging real-time patient feedback, JITAIs can deliver context-sensitive behavioral nudges and tailored psychological support at moments of heightened vulnerability, potentially mitigating anxiety associated with unpredictable exacerbations and improving long-term engagement62. At the same time, the application of AI raises important challenges related to regulation, algorithmic equity, and the digital divide, which should be addressed early in the design and implementation of digital health interventions63. However, several limitations must be acknowledged. The methodological quality of the included studies was variable. Among the six RCTs, four presented some risk of bias, while three of the five single-arm studies were rated as serious risk due to the absence of comparator groups37,38,42. Follow-up durations were generally ≤12 months, limiting the assessment of long-term effects. In addition, most studies did not report participants’ digital literacy, which may restrict generalisability to older or vulnerable populations. Outcome measures were heterogeneous (DLQI, Skindex, EQ-5D, CADI, CHU-9D, etc.). Previous teledermatology trials have reported more than 55 different instruments, with varying levels of validation, which complicates cross-study comparisons and limits the feasibility of meta-analysis64. Adoption of standardized Core Outcome Sets (COS), such as those proposed by the Cochrane Skin Group (CSG-COUSIN), may improve consistency of PRO measurement in future studies65. Furthermore, mediation analyses were rarely conducted, leaving the mechanisms linking DHIs to QoL improvements unclear. This review also has limitations. Restricting inclusion to English-language publications and excluding grey literature may have introduced language and publication bias. In addition, most studies were conducted in high-income countries, potentially limiting generalisability to low- and middle-income settings. Finally, although the WHO classification provides a standardized framework, it may oversimplify complex multi-component interventions. Overall, current evidence tentatively suggests that DHIs may improve quality of life and alleviate psychosocial burden among dermatology patients. However, the available evidence remains limited by methodological heterogeneity, variable risk of bias, and predominantly short-term follow-up. These findings should therefore be interpreted as exploratory rather than definitive. Future research should prioritize rigorously designed, long-term randomized trials, adopt standardized core outcome sets, and explore personalized, adaptive DHIs that better address individual psychosocial needs. Methods Study design and registration This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines66 and was prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO; ID: CRD420250628076). The completed PRISMA 2020 checklist is provided in Supplementary Table 4 and PRISMA 2020 for abstracts checklist is in Supplementary Table 5. Search strategy The search strategy was developed iteratively by the research team based on preliminary scoping searches, controlled vocabulary (MeSH and Emtree terms), and previously published systematic reviews. A comprehensive search was conducted in PubMed, Embase, the Cochrane Library, and Web of Science from database inception to June 2024. Search terms were structured around three key concepts: dermatologic conditions; digital health interventions; and quality of life. In addition to the database search, recently published studies (e.g., late 2024 to early 2025) were identified through manual screening of reference lists and were incorporated during manuscript preparation. Only studies published in English were included, and no restrictions were applied regarding publication year. The specific search queries used for each database are listed in Table 3.Table 3Search queries used in four databasesDatabasesSearch queriesPubMed(dermatolog*[Title/Abstract] OR skin disease*[Title/Abstract] OR skin disorder*[Title/Abstract] OR “Dermatology”[Mesh] OR “Skin Diseases”[Mesh]) AND (eHealth[Title/Abstract] OR mHealth[Title/Abstract] OR telehealth[Title/Abstract] OR telemedicine[Title/Abstract] OR digital health*[Title/Abstract] OR mobile health*[Title/Abstract] OR internet[Title/Abstract] OR “Telemedicine”[Mesh]) AND (“Quality of Life”[Mesh] OR quality of life[Title/Abstract] OR QoL[Title/Abstract] OR HRQoL[Title/Abstract] OR well-being[Title/Abstract] OR patient-reported outcome*[Title/Abstract]).Web of scienceALL = ((((“Dermatology” OR “Skin Disease” OR “Skin Cancer” OR dermatolog* OR skin disorder* OR “Skin Diseases”) AND (“Digital Technology” OR “Digital Health” OR “EHealth” OR “Telemedicine” OR “telehealth” OR “Mobile Applications” OR “MHealth” OR “E-Health” OR “M-Health” OR “eHealth” OR “mHealth” OR “e-health” OR “m-health” OR “internet” OR “telehealth” OR “digital” OR “internet”)) OR “teledermatology”)AND (“Quality of Life” OR “Health-Related Quality of Life” OR “QoL” OR “HRQoL” OR “Patient-Reported Outcomes” OR “well-being”)).Embase(dermatos*:ab OR skin disease*:ab OR skin disorder*:ab OR ‘Dermatology’/em OR ‘Skin Diseases’/em) AND (eHealth:ab OR mHealth:ab OR telehealth:ab OR telemedicine:ab OR digital health*:ab OR mobile health*:ab OR internet:ab OR ‘Telemedicine’/em) AND (‘Quality of Life’/em OR quality of life:ab OR QoL:ab OR HRQoL:ab OR well-being:ab OR patient-reported outcome*:ab).ScopusTITLE-ABS-KEY ((((“Dermatology” OR “Skin Disease” OR “Skin Cancer” OR dermatolog* OR skin AND disorder* OR “Skin Diseases”) AND (“Digital Technology” OR “Digital Health” OR “EHealth” OR “Telemedicine” OR “telehealth” OR “Mobile Applications” OR “MHealth” OR “E-Health” OR “M-Health” OR “eHealth” OR “mHealth” OR “e-health” OR “m-health” OR “internet” OR “telehealth” OR “digital” OR “internet”)) OR “teledermatology”) AND (“Quality of Life” OR “Health-Related Quality of Life” OR “QoL” OR “HRQoL” OR “Patient-Reported Outcomes” OR “well-being”)). Table 3Search queries used in four databasesDatabasesSearch queriesPubMed(dermatolog*[Title/Abstract] OR skin disease*[Title/Abstract] OR skin disorder*[Title/Abstract] OR “Dermatology”[Mesh] OR “Skin Diseases”[Mesh]) AND (eHealth[Title/Abstract] OR mHealth[Title/Abstract] OR telehealth[Title/Abstract] OR telemedicine[Title/Abstract] OR digital health*[Title/Abstract] OR mobile health*[Title/Abstract] OR internet[Title/Abstract] OR “Telemedicine”[Mesh]) AND (“Quality of Life”[Mesh] OR quality of life[Title/Abstract] OR QoL[Title/Abstract] OR HRQoL[Title/Abstract] OR well-being[Title/Abstract] OR patient-reported outcome*[Title/Abstract]).Web of scienceALL = ((((“Dermatology” OR “Skin Disease” OR “Skin Cancer” OR dermatolog* OR skin disorder* OR “Skin Diseases”) AND (“Digital Technology” OR “Digital Health” OR “EHealth” OR “Telemedicine” OR “telehealth” OR “Mobile Applications” OR “MHealth” OR “E-Health” OR “M-Health” OR “eHealth” OR “mHealth” OR “e-health” OR “m-health” OR “internet” OR “telehealth” OR “digital” OR “internet”)) OR “teledermatology”)AND (“Quality of Life” OR “Health-Related Quality of Life” OR “QoL” OR “HRQoL” OR “Patient-Reported Outcomes” OR “well-being”)).Embase(dermatos*:ab OR skin disease*:ab OR skin disorder*:ab OR ‘Dermatology’/em OR ‘Skin Diseases’/em) AND (eHealth:ab OR mHealth:ab OR telehealth:ab OR telemedicine:ab OR digital health*:ab OR mobile health*:ab OR internet:ab OR ‘Telemedicine’/em) AND (‘Quality of Life’/em OR quality of life:ab OR QoL:ab OR HRQoL:ab OR well-being:ab OR patient-reported outcome*:ab).ScopusTITLE-ABS-KEY ((((“Dermatology” OR “Skin Disease” OR “Skin Cancer” OR dermatolog* OR skin AND disorder* OR “Skin Diseases”) AND (“Digital Technology” OR “Digital Health” OR “EHealth” OR “Telemedicine” OR “telehealth” OR “Mobile Applications” OR “MHealth” OR “E-Health” OR “M-Health” OR “eHealth” OR “mHealth” OR “e-health” OR “m-health” OR “internet” OR “telehealth” OR “digital” OR “internet”)) OR “teledermatology”) AND (“Quality of Life” OR “Health-Related Quality of Life” OR “QoL” OR “HRQoL” OR “Patient-Reported Outcomes” OR “well-being”)). Search queries used in four databases Eligibility criteria Population Studies were included if they involved patients with a primary diagnosis of a dermatologic condition, including but not limited to psoriasis, atopic dermatitis, acne, chronic urticaria, and skin cancers. Studies focusing primarily on non-dermatologic systemic diseases (e.g., systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, or diabetic foot ulcers) were excluded, even if dermatologic manifestations were present. Interventions DHIs were defined as patient-facing interventions delivered through digital technologies, designed to improve health outcomes or patient experience67,68. Interventions were categorized according to the WHO Classification of Digital Health Interventions into four domains31: telemedicine (2.4), targeted client communication (1.1), personal health tracking (1.4), and client-to-client communication (1.3). Telemedicine includes remote consultations between clients and providers, remote monitoring of client health data, transmission of medical information, and case management between providers. In this review, telemedicine was treated as an active intervention rather than merely a delivery modality. Targeted client communication refers to the transmission of health information, alerts, or reminders to specific client populations with the aim of influencing health behaviour or supporting self-management. Personal health tracking refers to the use of mobile applications or wearable devices enabling patients to monitor their own health status. To qualify as an intervention, such tracking was required to include active components (e.g., reminders or educational content). Client-to-client communication refers to communication between patients as peers within organized digital communities or support groups. Because many real-world DHIs contain overlapping functions, each study was assigned to the domain that best reflected its primary intervention purpose. Eligible interventions included teledermatology and digitally mediated care delivery; mobile applications and digital self-management tools; online educational or behavioral interventions; and digital psychosocial or peer-support programs. Interventions were excluded if they consisted solely of diagnostic or triage-focused artificial intelligence tools, provider-only digital systems, or monitoring-only tools without a clear interventional intent. Outcomes The primary outcome was QoL, defined as: outcomes measured using validated QoL instruments (e.g., DLQI, EQ-5D, Skindex), or explicitly reported patient-centered outcomes related to QoL domains. All instruments listed above were used exclusively as validated outcome measures and did not serve as interventional components of any digital health intervention. Guided by the National Institutes of Health (NIH) Patient-Reported Outcomes Measurement Information System (PROMIS)46,47, the secondary patient-centered outcomes were systematically categorized into three fundamental domains: mental health, self-efficacy, and social health. Studies without outcome data related to QoL were excluded. Study design RCTs, prospective single-arm studies (encompassing feasibility, pretest-posttest, and interventional designs), observational and cross-sectional studies were included. Reviews, commentaries, case reports, conference abstracts, and non-peer-reviewed materials were excluded. Study selection All records were imported into Zotero for deduplication. Two reviewers (Y.C. and X.L.) independently screened titles and abstracts to exclude irrelevant studies, followed by full-text screening to assess eligibility based on the predefined criteria. Disagreements were resolved by a third reviewer (L.G.) through discussion and consensus. Data extraction A standardized data extraction form was used to collect key study characteristics, including the first author, year of publication, country, study design, sample size, recruitment method, follow-up duration, dermatologic condition, type of DHI, comparator, QoL assessment tools, and key outcomes. While comprehensively validated instruments remain the standard for quantifying health-related QoL, dermatologic research frequently utilizes custom questionnaires or specific psychological metrics. To ensure a comprehensive synthesis of patient-reported outcomes and address this methodological heterogeneity, we adopted a multidimensional approach during data extraction using established frameworks. Data extraction was conducted independently by two reviewers (Y.C. and X.L.). Any discrepancies were resolved through discussion, with involvement of a third reviewer (L. G.) where necessary. Data synthesis Given the substantial heterogeneity in study designs, intervention types, and outcome measures, a quantitative meta-analysis was not feasible. Therefore, we conducted a structured narrative synthesis. QoL and related patient-centered outcomes were grouped according to the four predefined WHO categories of DHIs: telemedicine, targeted client communication, personal health tracking, and client-to-client communication. For each category, we summarized the number of studies, study designs, participant characteristics, QoL measures, and direction of effect (positive, neutral, or negative) for global QoL and patient-centered outcomes (mental health, self-efficacy, social health). Implementation and engagement outcomes were grouped according to the NIH PROMIS: mental health; self-efficacy; and social health. Findings were reported descriptively without statistical pooling. Risk of bias and quality assessment Given the methodological heterogeneity of included studies, design-specific tools were used to ensure appropriate and rigorous assessment of risk of bias. Randomized controlled trials were assessed using the Cochrane RoB 2 tool48. Non-randomized interventional studies were evaluated using the ROBINS-I tool49. Observational and cross-sectional studies were appraised using the JBI critical appraisal checklists appropriate to each study design50. All assessments were performed independently by two reviewers (Y.C. and X.L.), with disagreements resolved through discussion with a third reviewer (L.G.). Supplementary information Supplementary Information Supplementary Information